Dillon et al., Induction of Protective Class I MHC-Restricted CTL in Mice By a Recombinant Influenza Vaccine in Aluminum Hydroxide Adjuvant, Vaccine, vol. 10, Issue 5, pp. 309-318, 1992.* |
Ionita et al., Archives Roumaines Depathologie Experimentales Et De Microbiologie, 1989 (Jul.-Sep.) 48(3) 265-73.* |
Mumford et al., Epidemiology and Infection (Apr.1994) 112(2) 421-37.* |
Bachmayer, H.; Split and Subunit Vaccines; Influenza: Virus, Vaccines, Strategy (Editor P. Selby); Academic Press, New York; pp. 149-152 (1976). |
Coulter, A., et al.; Studies on Experimental Adjuvanted Influenza Vaccines: Comparison of Immune Stimulating Complexes (Iscoms™) and Oil-in Water Vaccines; Vaccine; vol. No. 16:11/12; pp. 1243-1253 (1998). |
Davenport, F.M., et al.; Lack of Adjuvant Effect of AIPO4 on Purified Influenza Virus Hemagglutinins in Man; The Journal of Immunology; vol. 100, No. 5, pp. 1139-1140 (1968). |
Fukumi, H.; Effectiveness and Untoward Reactions of Oil Adjuvant Influenza Vaccines; Symp. Series Immunobiol. Standard; vol. 6; pp. 237-240 (1967). |
Guaraccia, S., et al.; A Comparative Immunogenicity-Reactogenicity Dose-Response Study of Influenza Vaccine; Annals of Allergy; vol. 65; pp. 218-221 (Sep. 1990). |
Hjorth, R.N., et al.; The Effect of Syntex Adjuvant Formulation (SAF-m) on Humoral Immunity to the Influenza Virus in the Mouse; Vaccine; vol. 15:5; pp. 541-546 (1997). |
Jennings, R., et al.; Responses of Volunteers to Inactivated Influenza Virus Vaccines; Journal of Hygiene; vol. 86:1; pp. 1-16 (1981). |
Keitel, W., et al.; Pilot Evaluation of Influenza Virus Vaccine (IVV) Combined with Adjuvant; Vaccine; vol. 11:9; pp. 909-913 (1993). |
Kistner, O., et al.; Development of a Mammalian Cell (Vero) Derived Candidate Influenza Virus Vaccine; Vaccine; vol. 16:9/10; pp. 960-968 (1998). |
Kistner, O., et al.; Development of a Vero Cell-Derived Influenza Whole Virus Vaccine; Dev Biol Stand; vol. 98; pp. 101-110 (1999). |
Martin, J.T.; Development of an Adjuvant to Enhance the Immune Response to Influenza Vaccine in the Elderly; Biologicals; vol. 25; pp. 209-213 (1997). |
Merten, O.W., et al.; Production of Influenza Virus in Serum-Free Mammalian Cell Cultures; Dev Biol Stand; vol. 98; pp. 23-37 (1999). |
Nicholson, K.G., et al.; Clinical Studies of Monovalent Inactivated Whole Virus and Subunit A/USSR/77 (H1N1) Vaccine: Serological Responses and Clinical Reactions; Journal of Biol. Stand.; vol. 7; pp. 123-136 (1979). |
Palache, A.M., et al.; Antibody Response after Influenza Immunization with Various Vaccine Doses: A Doubl-Blind, Placebo-Controlled, Multi-Centre, Dose-Response Study in Elderly Nursing-Home Residents and Young Volunteers; Vaccine; vol. 11:1;pp. 3-9 (1993). |
Palache, A.M., et al.; Influenza Vaccines: The Effect of Vaccine Dose on Antibody Response in Primed Populations During the Ongoing Interpandemic Period—A Review of the Literature; Vaccine; vol. 11:9; pp. 892-908 (1993). |
Palmer, D.F., et al.; A Procedural Guide to the Performance of Rubella Hemagglutination-Inhibition Tests; U.S. Dept. of Health, Ed. and Welfare, PHS, Atlanta, GA; pp. 25-62 (1977). |
Robuccio, J.A., et al.; Comparison of the Effects of Five Adjuvants on the Antibody Response to Influenza Virus Antigen in Guinea Pigs; Lab Animal Science; vol. 45;4; pp. 420-426 (1995). |
Skea, D.L., et al.; Adhesion-Mediated Enhancement of the Adjuvant Activity of Alum; Vaccine; vol. 11:10; pp. 1018-1026 (1993). |
Committee for Proprietary Medicinal Products (CPMP): Note for Guidance on Harmonisation of Requirements for Influenza Vaccines (CPMP/BWP/214/96);pp. 20-21 (1996). |